Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Oncocyte Corp (OCX)
|
Add to portfolio |
|
|
|
| Price: |
$4.96
| | Metrics |
| OS: |
8.24
|
M
| |
|
|
| Market cap: |
$40.9
|
M
| |
|
|
|
Net cash:
|
$17.9
|
M
| |
$2.17
|
per share
|
|
EV:
|
$23
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 1.0 | 7.7 | 1.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | -87.6% | 535.4% | | | | | | |
| Cost of goods sold | 1.0 | 4.2 | 1.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 3.5 | -0.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | -1.9% | 45.8% | -52.5% | | | | | |
| Sales and marketing | 1.1 | 11.2 | 6.5 | 2.2 | 1.7 | 2.4 | 1.2 | 0.3 |
| Research and development | 7.3 | 13.6 | 9.8 | 6.8 | 6.5 | 7.2 | 5.7 | 4.5 |
| General and administrative | 21.9 | 22.3 | 16.8 | 13.3 | 7.0 | 9.2 | 4.3 | 3.9 |
| EBITA | -30.3 | -70.6 | -28.1 | -22.5 | -15.1 | -18.6 | -10.9 | -8.5 |
| EBITA margin | -3166.2% | -913.4% | -2309.5% | | | | | |
| Amortization of intangibles | | 3.4 | 0.1 | | 0.1 | 0.2 | 0.2 | 0.2 |
| EBIT | -30.3 | -73.9 | -28.2 | -22.5 | -15.2 | -18.8 | -11.1 | -8.7 |
| EBIT margin | -3166.2% | -956.9% | -2316.1% | | | | | |
| Pre-tax income | -18.6 | -73.4 | -31.2 | -22.4 | -15.8 | -19.4 | -11.2 | -8.7 |
| Income taxes | 0.0 | -9.3 | -1.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 12.6% | 4.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -72.9 | -64.1 | -29.9 | -22.4 | -15.8 | -19.4 | -11.2 | -8.7 |
| Net margin | -7609.8% | -829.5% | -2461.5% | | | | | |
| |
| Diluted EPS | | ($0.72) | ($0.46) | ($0.44) | ($0.42) | ($0.64) | ($0.42) | ($0.42) |
| Shares outstanding (diluted) | | 88.9 | 65.5 | 51.3 | 37.9 | 30.2 | 26.5 | 21.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|